Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Esophageal Neoplasms 4Nasopharyngeal Carcinoma 3Carcinoma, Non-Small-Cell Lung 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2Head and Neck Neoplasms 2Stomach Neoplasms 1Resectable Pancreatic Cancer 1Penile Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Glioma 1Glioblastoma 1Esophageal 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Advanced and/or Metastatic Solid Tumours 1Advanced Esophageal 1Adenocarcinoma 1

Interventions

Fluorouracil 255Leucovorin 224Oxaliplatin 218Irinotecan 206Bevacizumab 200Capecitabine 144Cetuximab 136Panitumumab 68Folfox protocol 63regorafenib 50Colonoscopy 44pembrolizumab 42IFL protocol 39Radiotherapy 32Nivolumab 31Drug Therapy 27trifluridine tipiracil drug combination 26Gemcitabine 24Blood Specimen Collection 23Chemotherapy, Adjuvant 20Surveys and Questionnaires 19Celecoxib 19Surgical Procedures, Operative 16durvalumab 15Neoadjuvant Therapy 15Cyclophosphamide 14Cisplatin 14aflibercept 13Standard of Care 13Pemetrexed 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Colorectal Neoplasms × nimotuzumab × Clear all
NCT05278728 2025-02-07

Phase IIa Study of Nimotuzumab to Treat Colorectal Cancer

Biotech Pharmaceutical Co., Ltd.

Phase 1/2 Completed
31 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡